Pfizer Sees 5% Growth In Second Half; Currency, Competition Hurt Sales
Executive Summary
Pfizer's revised forecast for 2004 revenues indicates that the company expects sales growth of about 5% during the second half of the year
You may also be interested in...
Pfizer’s New Benchmark For New Era: 8% Annual Growth Is Sustainable
The pharmaceutical industry is entering a period where average annual growth rates are likely to hover at about 8%, Pfizer CEO Hank McKinnell predicted during a Nov. 30 analyst meeting in Groton, Conn
Pfizer’s New Benchmark For New Era: 8% Annual Growth Is Sustainable
The pharmaceutical industry is entering a period where average annual growth rates are likely to hover at about 8%, Pfizer CEO Hank McKinnell predicted during a Nov. 30 analyst meeting in Groton, Conn
Vioxx Shock Is Latest Headache For Rx Stocks; Is Election Day A Cure?
Pfizer's $27 bil. devaluation during the third quarter is strong evidence that Wall Street's aversion to drug stocks goes far beyond the Vioxx withdrawal